title: Prospective study of special stage II (T2b-3N0M0) non-small-cell lung cancer treated with hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy.
abstract: OBJECTIVE
  To analyze the effects of hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy (Hypo-SIB-IMRT) on medically inoperable patients with special stage II (T2b-3N0M0) non-smallcell lung cancer (NSCLC).
  
  
  METHODS
  Twenty-eight qualified patients were included. Hypo-SIB-IMRT was delivered with internal gross tumor volume (iGTV) 75 Gy, clinical target volume (CTV) 60 Gy, and planning target volume (PTV) 45 Gy on weekdays in 3 weeks.
  
  
  RESULTS
  The 1-, 2-, and 3-year overall survivals (OSs) were 93, 85, and 61%, respectively, with a median survival of 46.5 months; while progression-free survivals (PFSs) were 92, 79, and 64%; and distant metastasis-free survivals (DMFSs) were 92, 84, and 77%, respectively. The cancer-specific survivals (CSS) were 93, 88, and 74%, and local control (LC) were 92, 83, and 74%, respectively. 7.1% (2/28) of patients occurred local pain, 28.6% (8/28) were with Grade 1 or 2 radiation pneumonitis (RP), and 7.1% (2/28) with Grade 1 esophagitis. Of the eight patients with RP, 17.9% (5/28) developed Grade 1 radiation pulmonary fibrosis (RPF).
  
  
  CONCLUSIONS
  Due to the favorable long-term survivals, LC, and minimal toxicities, Hypo-SIB-IMRT presented in this prospective study may be considered an option for patients with special stage II (T2b-3N0M0) NSCLC who were medically inoperable.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Chengxin
authors.initials: C
authors.lastname: Liu
authors.forename: Haiqun
authors.initials: H
authors.lastname: Lin
authors.forename: Yipeng
authors.initials: Y
authors.lastname: Song
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.forename: Hongsheng
authors.initials: H
authors.lastname: Li
authors.forename: Miaomiao
authors.initials: M
authors.lastname: Li
authors.affiliation: Department of Radiation Oncology VI, Shandong Cancer Hospital, 440 Jiyan Road, Huaiyin Area, Jinan, Shandong province, China.
authors.forename: Baosheng
authors.initials: B
authors.lastname: Li
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000473:pathology* / Q000532:radiotherapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology* / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging / Q000379:methods; D011446:Prospective Studies; D011832:Radiation Injuries / Q000209:etiology; D017564:Radiation Pneumonitis / Q000209:etiology; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000009:adverse effects / Q000379:methods; D050397:Radiotherapy, Intensity-Modulated / Q000009:adverse effects / Q000379:methods